Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Generics and Original Drugs Are Not the Same: Prof. Uchida
June 4, 2007
- SELF-MEDICATION NEWS IN BRIEF
June 4, 2007
- Mochida: Epadel, Atelec Drive Business
May 28, 2007
- Kissei: New Drugs Drive Business
May 28, 2007
- BUSINESS NEWS IN BRIEF
May 28, 2007
- Mitsubishi Tanabe Pharma Corp. Aims at Becoming "Global Drug Discovery Company"
May 28, 2007
- Further Revision of Prescription Form Discussed at Chuikyo
May 28, 2007
- Korosho Proposes Increasing Generics' Share to 30% by FY2012
May 28, 2007
- JSMI General Assembly
May 28, 2007
- GENERICS NEWS IN BRIEF
May 28, 2007
- Baxter Focuses on BioScience, Med. Delivery, Renal Therapies: Mr Lema
May 28, 2007
- R&D NEWS IN BRIEF
May 28, 2007
- Top 4 Companies Show Strong Global Sales
May 28, 2007
- Relation between Tamiflu and Sleep to Be Investigated in Clinical Study
May 28, 2007
- Daiichi Sankyo: Growing Sales of Olmesartan Offset Declining Sales of Pravastatin
May 28, 2007
- MOF Questions Insurance Coverage of OTC-Like Drugs
May 28, 2007
- Astellas: Sales Up 4.7% to \920,624 Mil. with 48.9% Overseas
May 28, 2007
- REGULATORY NEWS IN BRIEF
May 28, 2007
- Eisai: Record-High Sales with Increases in Profits 7 Years in a Row
May 28, 2007
- MEDICAL DEVICE NEWS IN BRIEF
May 28, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…